RxDoctor Payments Data

Ahmet Sevimli, MD

Nephrology · Orange City, FLNPI 1912096629

Payments from drug & device makers

$3,151in general payments, 2019–2025

Across 129 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$673
  • Calliditas Therapeutics US Inc.$499
  • Amgen$443
  • Novartis$204
  • Vantive US Healthcare LLC$191
  • Travere Therapeutics, Inc.$169
  • plus $971 from 15 others

What the payments were for

  • Food & beverage$3,02596%
  • Education$1264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,151 in reported general payments places this provider in the 60th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$257,015
Medicare patients
660
Services billed
2,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$48,040
FarxigaDapagliflozin Propanediol37$37,004
VeltassaPatiromer Calcium Sorbitex15$18,299
LokelmaSodium Zirconium Cyclosilicate15$12,270
Cinacalcet Hcl18$3,646
Potassium Citrate ErPotassium Citrate16$1,160
Hydralazine Hcl54$1,024
Amlodipine Besylate128$902
Carvedilol38$496
Lisinopril67$433
Losartan Potassium33$336
Calcitriol33$320
Clonidine Hcl27$190
Furosemide21$112
Hydrochlorothiazide20$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$142$49,27452 claims
Boehringer IngelheimJardiance$29$48,04055 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 756 nephrology providers in Florida.

Other nephrology in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →